Literature DB >> 31400163

Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth.

Jiping Wang1, Jianmei W Leavenworth2,3, Anita B Hjelmeland4, Reed Smith1, Neha Patel1, Ben Borg1, Ying Si1, Peter H King1,4,5.   

Abstract

Glioblastoma is a malignant brain tumor that portends a poor prognosis. Its resilience, in part, is related to a remarkable capacity for manipulating the microenvironment to promote its growth and survival. Microglia/macrophages are prime targets, being drawn into the tumor and stimulated to produce factors that support tumor growth and evasion from the immune system. Here we show that the RNA regulator, HuR, plays a key role in the tumor-promoting response of microglia/macrophages. Knockout (KO) of HuR led to reduced tumor growth and proliferation associated with prolonged survival in a murine model of glioblastoma. Analysis of tumor composition by flow cytometry showed that tumor-associated macrophages (TAMs) were decreased, more polarized toward an M1-like phenotype, and had reduced PD-L1 expression. There was an overall increase in infiltrating CD4+ cells, including Th1 and cytotoxic effector cells, and a concomitant reduction in tumor-associated polymorphonuclear myeloid-derived suppressor cells. Molecular and cellular analyses of HuR KO TAMs and cultured microglia showed changes in migration, chemoattraction, and chemokine/cytokine profiles that provide potential mechanisms for the altered tumor microenvironment and reduced tumor growth in HuR KO mice. In summary, HuR is a key modulator of pro-glioma responses by microglia/macrophages through the molecular regulation of chemokines, cytokines, and other factors. Our findings underscore the relevance of HuR as a therapeutic target in glioblastoma.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cell migration; cytokines; effector T cells; glioblastoma; tumor microenvironment; tumor-associated macrophages and microglia

Mesh:

Substances:

Year:  2019        PMID: 31400163      PMCID: PMC7008520          DOI: 10.1002/glia.23696

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  78 in total

Review 1.  Bringing the role of mRNA decay in the control of gene expression into focus.

Authors:  Carol J Wilusz; Jeffrey Wilusz
Journal:  Trends Genet       Date:  2004-10       Impact factor: 11.639

2.  Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain.

Authors:  L J Lawson; V H Perry; P Dri; S Gordon
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

3.  Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.

Authors:  Takuro Noguchi; Jeffrey P Ward; Matthew M Gubin; Cora D Arthur; Sang Hun Lee; Jasreet Hundal; Mark J Selby; Robert F Graziano; Elaine R Mardis; Alan J Korman; Robert D Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-10       Impact factor: 11.151

Review 4.  RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins.

Authors:  Mingui Fu; Perry J Blackshear
Journal:  Nat Rev Immunol       Date:  2016-12-19       Impact factor: 53.106

5.  Hu antigen R (HuR) multimerization contributes to glioma disease progression.

Authors:  Natalia Filippova; Xiuhua Yang; Subramaniam Ananthan; Anastasia Sorochinsky; James R Hackney; Zachery Gentry; Sejong Bae; Peter King; L Burt Nabors
Journal:  J Biol Chem       Date:  2017-08-08       Impact factor: 5.157

Review 6.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells.

Authors:  Lei Wang; Ziyan Liu; Sivasai Balivada; Tej Shrestha; Stefan Bossmann; Marla Pyle; Loretta Pappan; Jishu Shi; Deryl Troyer
Journal:  Stem Cell Res Ther       Date:  2012-02-10       Impact factor: 6.832

8.  Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Réjean Lapointe
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

9.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.

Authors:  Vikram R Juneja; Kathleen A McGuire; Robert T Manguso; Martin W LaFleur; Natalie Collins; W Nicholas Haining; Gordon J Freeman; Arlene H Sharpe
Journal:  J Exp Med       Date:  2017-03-16       Impact factor: 14.307

10.  Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

Authors:  Matthew A Coelho; Sophie de Carné Trécesson; Sareena Rana; Davide Zecchin; Christopher Moore; Miriam Molina-Arcas; Philip East; Bradley Spencer-Dene; Emma Nye; Karin Barnouin; Ambrosius P Snijders; Wi S Lai; Perry J Blackshear; Julian Downward
Journal:  Immunity       Date:  2017-12-12       Impact factor: 31.745

View more
  13 in total

Review 1.  Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.

Authors:  Rajeswari Raguraman; Akhil Srivastava; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-08-08       Impact factor: 15.470

Review 2.  The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.

Authors:  Abhishek Guha; Saboora Waris; Louis B Nabors; Natalia Filippova; Myriam Gorospe; Thaddaeus Kwan; Peter H King
Journal:  Adv Drug Deliv Rev       Date:  2021-12-16       Impact factor: 15.470

Review 3.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

4.  SRI-42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammation.

Authors:  Rajeshwari Chellappan; Abhishek Guha; Ying Si; Thaddaeus Kwan; Louis B Nabors; Natalia Filippova; Xiuhua Yang; Anish S Myneni; Shriya Meesala; Ashley S Harms; Peter H King
Journal:  Glia       Date:  2021-09-17       Impact factor: 7.452

5.  Inhibition of the RNA Regulator HuR by SRI-42127 Attenuates Neuropathic Pain After Nerve Injury Through Suppression of Neuroinflammatory Responses.

Authors:  Robert E Sorge; Ying Si; Lyse A Norian; Abhishek Guha; Grace E Moore; L Burt Nabors; Natalia Filippova; Xiuhua Yang; Reed Smith; Rajeshwari Chellappan; Peter H King
Journal:  Neurotherapeutics       Date:  2022-07-21       Impact factor: 6.088

6.  Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors.

Authors:  Natalia Filippova; Xiuhua Yang; Subramaniam Ananthan; Jennifer Calano; Vibha Pathak; Larry Bratton; Rakesh H Vekariya; Sixue Zhang; Edward Ofori; Emily N Hayward; David Namkoong; David K Crossman; Michael R Crowley; Peter H King; James Mobley; Louis B Nabors
Journal:  Cancer Res       Date:  2021-02-18       Impact factor: 13.312

Review 7.  Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.

Authors:  Jun Ma; Clark C Chen; Ming Li
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

8.  Butyric acid alleviated chronic intermittent hypoxia-induced lipid formation and inflammation through up-regulating HuR expression and inactivating AMPK pathways.

Authors:  MiaoShang Su; Yifan He; Sichen Xue; Jueke Yu; Xikai Ren; Nan Huang; Rukkaiya Abdullahi; Manhuan Xu
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

9.  Demeclocycline Reduces the Growth of Human Brain Tumor-Initiating Cells: Direct Activity and Through Monocytes.

Authors:  Susobhan Sarkar; Yibo Li; Reza Mirzaei; Khalil S Rawji; Candice C Poon; Jianxiong Wang; Mehul Kumar; Pinaki Bose; V Wee Yong
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

10.  Computational analysis and verification of molecular genetic targets for glioblastoma.

Authors:  Liang Xue; Haibing Liu; Yehuang Chen; Liangfeng Wei; Jingfang Hong
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.